Furthermore, STAT3 activation seems to play a crucial role in the development of resistance to Sorafenib, a multi-tyrosine kinase inhibitor used in clinical practice to treat advanced HCC, by the regulation of an anti-apoptotic protein, Mcl-1 [66]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.